Blar i Bergen Open Research Archive på forfatter "Engerud, Hilde Renate"

Viser treff 1-4 av 4

    • High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer 

      Engerud, Hilde Renate; Berg, Hege Fredriksen; Myrvold, Madeleine; Halle, Mari Kyllesø; Bjørge, Line; Haldorsen, Ingfrid S.; Høivik, Erling Andre; Trovik, Jone; Krakstad, Camilla (Journal article; Peer reviewed, 2020)
      Objective PD-L1 and PD-1 are predictive markers for immunotherapy and increasingly relevant in endometrial cancer. The reported fraction of positive primary tumors has been inconsistent. We investigated the expression of ...

    • Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer 

      Forsse, David Erik; Berg, Hege Fredriksen; Bozickovic, Olivera; Engerud, Hilde Renate; Halle, Mari Kyllesø; Høivik, Erling Andre; Woie, Kathrine; Werner, Henrica Maria Johanna; Haldorsen, Ingfrid S.; Trovik, Jone; Krakstad, Camilla (Journal article; Peer reviewed, 2020)
      Objective Main controversies in endometrial cancer treatment include the role of lymphadenectomy and optimal adjuvant treatment. We assessed clinical outcome in a population-based endometrial cancer cohort in relation to ...

    • Molecular markers to predict prognosis and guide therapy in endometrial cancer 

      Engerud, Hilde Renate (Doctoral thesis, 2020-02-07)
      Background: Endometrial cancer is the most common gynecological malignancy in the Western world. The disease occurs in the epithelial lining of the uterus, called the endometrium. Although prognosis is good and most of the ...

    • Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer 

      Engerud, Hilde Renate; Hope, Kirsten Øvergaard; Berg, Hege Fredriksen; Fasmer, Kristine Eldevik; Tangen, Ingvild Løberg; Haldorsen, Ingfrid S.; Trovik, Jone; Krakstad, Camilla (Peer reviewed; Journal article, 2019)
      Objective: Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk of recurrence and who may profit from a more aggressive treatment regimen. Our objective was to explore the applicability ...